Solid Biosciences Inc logo

SLDB

Solid Biosciences Inc

$0.81

Earnings Summary

Revenue
$1.93Mn
Net Profits
$-25.33Mn
Net Profit Margins
-1315.74%

Highlights

Revenue:

Solid Biosciences Inc’s revenue fell -42.28% since last year same period to $1.93Mn in the Q1 2022. On a quarterly growth basis, Solid Biosciences Inc has generated -38.97% fall in its revenue since last 3-months.

Net Profits:

Solid Biosciences Inc’s net profit fell -49.87% since last year same period to $-25.33Mn in the Q1 2022. On a quarterly growth basis, Solid Biosciences Inc has generated -36.1% fall in its net profits since last 3-months.

Net Profit Margins:

Solid Biosciences Inc’s net profit margin fell -159.64% since last year same period to -1315.74% in the Q1 2022. On a quarterly growth basis, Solid Biosciences Inc has generated -122.99% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Solid Biosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.21
EPS Estimate Current Year
-0.21

Highlights

EPS Estimate Current Quarter:

Solid Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.21 - a -16.67% fall from last quarter’s estimates.

EPS Estimate Current Year:

Solid Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.21.

Key Ratios

Key ratios of the Solid Biosciences Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.22
Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-0.43
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Solid Biosciences Inc’s earning per share (EPS) fell -15.79% since last year same period to -0.22 in the Q1 2022. This indicates that the Solid Biosciences Inc has generated -15.79% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Solid Biosciences Inc’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Solid Biosciences Inc’s return on equity (ROE) stands at -0.43.

Dividend Per Share (DPS):

Solid Biosciences Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-04-27
-0.18
-0.22
-22.22%

Company Information

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, its mandate is simple yet comprehensive - work to address the disease at its core by correcting the underlying mutation that causes Duchenne with its lead gene therapy candidate, SGT-001.

Organisation
Solid Biosciences Inc
Employees
70
Industry
Health Technology